Fraiser Kansteiner

Despite recent developments in the fight to corral high U.S. drug prices, the trend toward consistently rising costs—which has held true for years—is likely to persist for the foreseeable future.

Despite weathering significant criticism from lawmakers and patient groups over the steep cost of its rare disease med Firdapse, Catalyst Pharmaceutical has repeatedly emerged triumphant over its detractors.

Just two weeks into 2025, January is proving why it's earned a reputation as the worst month for layoffs.

Less than two months after scoring what analysts deemed a "best-case" FDA approval for its cardiomyopathy drug Attruby, California's BridgeBio is stepping into the spotlight of the J.P.

The first day of the J.P. Morgan Healthcare Conference is in the books, featuring high-profile deal announcements from Johnson & Johnson, Eli Lilly, GSK and several other biopharma players.

Among the myriad drugmakers laying out their plans for the future at this year's J.P. Morgan Healthcare Conference, Takeda said it's laser-focused on six pipeline assets that could each reel in blockbuster-level sales down the line.

Following the strange year for the biopharma industry that was 2024, insiders and analysts alike are waiting expectantly to see how trends in

In the ongoing quest to expand semaglutide's clinical pedigree and cement the GLP-1's market position, Novo Nordisk is rolling out new data on a higher-dose injection in obesity.

Despite receiving a prior wrist slap from the FDA in the shape of a Form 483, Sanofi is still working to right the ship at a U.S. drug ingredients plant tied to its longstanding subsidiary Genzyme.

As Stelara biosimilars chip away at sales in Europe and off-brand rivals start to grace the stage in the U.S., Johnson & Johnson is confident it can eke out revenue growth this year despite the steady decline of one of its most prominent blockbusters.